Download MendeleyBenzensulfonamides bearing spyrohydantoin moieties act as potent inhibitors of human carbonic anhydrases II and VII and show neuropathic pain attenuating effects.
Angeli, A., Di Cesare Mannelli, L., Ghelardini, C., Peat, T.S., Bartolucci, G., Menicatti, M., Carta, F., Supuran, C.T.(2019) Eur J Med Chem 177: 188-197
- PubMed: 31136893
- DOI: https://doi.org/10.1016/j.ejmech.2019.05.058
- Primary Citation of Related Structures:
6ODZ, 6OE0, 6OE1 - PubMed Abstract:
Carbonic Anhydrases have been recently validated as novel therapeutic targets in neuropathic pain. In this study, we combine the anticonvulsant propriety of spyrohydantoin and the CA inhibitor moiety of benzenesulfonamide to synthesize a novel series of spyrohydantoin bearing sulfonamides with strong activity against hCA II and VII. These isoforms are present in the nervous system and largely expressed both at the central as well as at peripheral level and can be modulated for pain relief. The crystal structures of hCA II in complex with selected compounds 5a-c demonstrate the importance of the tail in the binding modes within the isoform. Finally, in vivo, in an animal model of oxaliplatin induced neuropathy, compounds with organoselenium tails (8b-c) showed potent neuropathic pain attenuating effects. Taken together, these data strongly suggest the translational utility of these inhibitors as novel pain relievers.
Organizational Affiliation:
University of Florence, NEUROFARBA Dept., Sezione di Scienze Farmaceutiche, Via Ugo Schiff 6, 50019, Sesto Fiorentino, Florence, Italy.
